 | • レポートコード：MRC-IM30292 • 出版社/出版日：IMARC / 2022年11月 • レポート形態：英文、PDF、145ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥369,852 (USD2,499) | ▷ お問い合わせ |
| Enterprisewide | ￥665,852 (USD4,499) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| グローバル調査会社のIMARC社は、2021年に23億ドルであった世界のワクチン受託製造市場規模が、2022年から2027年の間にCAGR 10.12％で成長し、2027年までに40億ドルに達すると予測しています。本調査レポートでは、ワクチン受託製造の世界市場について総合的に調査・分析し、序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、ワクチン種類別（弱毒化ワクチン、不活化ワクチン、サブユニットワクチン、トキソイドワクチン、DNAワクチン）分析、ワークフロー別（下流、上流）分析、用途別（ヒト用、動物用）分析、地域別（北米、アジア、欧州、中南米、中東・アフリカ）分析、SWOT分析（強み・弱み・機会・脅威）、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などの項目をまとめています。なお、本書に掲載されている企業情報には、Ajinomoto Co. Inc., Albany Molecular Research Inc, Catalent Inc, Cobra Biologics Limited (Charles River Laboratories International Inc.), Cytovance Biologics Inc. (Hepalink USA Inc.), Fujifilm Holdings Corporation, ICON plc, IDT Biologika GmbH, Lonza Group AG, Merck KGaAなどが含まれています。 ・序論 ・範囲・調査手法 ・エグゼクティブサマリー ・イントロダクション ・世界のワクチン受託製造市場規模：ワクチン種類別 - 弱毒化ワクチンの市場規模 - 不活化ワクチンの市場規模 - サブユニットワクチンの市場規模 - トキソイドワクチンの市場規模 - DNAワクチンの市場規模 ・世界のワクチン受託製造市場規模：ワークフロー別 - 下流ワークフローの市場規模 - 上流ワークフローの市場規模 ・世界のワクチン受託製造市場規模：用途別 - ヒト用ワクチンの市場規模 - 動物用ワクチンの市場規模 ・世界のワクチン受託製造市場規模：地域別 - 北米のワクチン受託製造市場規模 - アジアのワクチン受託製造市場規模 - 欧州のワクチン受託製造市場規模 - 中南米のワクチン受託製造市場規模 - 中東・アフリカのワクチン受託製造市場規模 ・SWOT分析（強み・弱み・機会・脅威） ・バリューチェーン分析 ・ファイブフォース分析 ・価格分析 ・競争状況 |
The global vaccine contract manufacturing market size reached US$ 2.3 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 4.0 Billion by 2027, exhibiting a growth rate (CAGR) of 10.12% during 2022-2027.
Vaccine contract manufacturing refers to the outsourcing of large-scale production of vaccines to contract manufacturing organizations (CMOs). These organizations offer numerous services, including pre-formulation work, formulation development, method development, stability studies, pre-clinical activities, registration batches and commercial manufacturing. Apart from this, they provide expertise and innovative technologies to expand the production chain of pharmaceutical companies. At present, the demand for outsourcing vaccine manufacturing activities is escalating worldwide on account of reduced development costs and complex production protocols.
Vaccination plays a pivotal role in improving human as well as veterinary health. It reduces the need for antibiotics and prevents diseases. The increasing awareness about vaccination and numerous associated benefits, such as protection from severe illnesses and infectious diseases, is catalyzing the demand for immunization programs and inoculations. This, in confluence with understanding the complexity of capital requirement for production, has led the leading pharmaceutical companies to outsource vaccine manufacturing. Apart from this, the lack of equipment and skilled labor for vaccine production in low-resource countries is also contributing to the global vaccine contract manufacturing market growth. Moreover, technological advancements, including the introduction of expression systems like the EB66 and GPEx and cell culture media platforms, are supporting the market growth. Furthermore, the alarmingly growing cases of coronavirus disease (COVID-19) in numerous countries have propelled the vaccine developers to sign outsourcing agreements with CMOs. This is creating a favorable outlook for the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine contract manufacturing market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on vaccine type, workflow and application.
Breakup by Vaccine Type:
Attenuated
Inactivated
Subunit-based
Toxoid-based
DNA-based
Breakup by Workflow:
Downstream
Fill and Finish Operations
Analytical and QC Studies
Packaging
Upstream
Mammalian Expression Systems
Bacterial Expression Systems
Yeast Expression Systems
Baculovirus/Insect Expression Systems
Others
Breakup by Application:
Human Use
Veterinary
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Ajinomoto Co. Inc., Albany Molecular Research Inc, Catalent Inc, Cobra Biologics Limited (Charles River Laboratories International Inc.), Cytovance Biologics Inc. (Hepalink USA Inc.), Fujifilm Holdings Corporation, ICON plc, IDT Biologika GmbH, Lonza Group AG, Merck KGaA, Pharmaceutical Product Development LLC and PRA Health Sciences Inc.
Key Questions Answered in This Report:
How has the global vaccine contract manufacturing market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global vaccine contract manufacturing market?
What are the key regional markets?
What is the breakup of the market based on the vaccine type?
What is the breakup of the market based on the workflow?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global vaccine contract manufacturing market and who are the key players?
What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Vaccine Contract Manufacturing Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Vaccine Type
6.1 Attenuated
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Inactivated
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Subunit-based
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Toxoid-based
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 DNA-based
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Workflow
7.1 Downstream
7.1.1 Market Trends
7.1.2 Key Segments
7.1.2.1 Fill and Finish Operations
7.1.2.2 Analytical and QC Studies
7.1.2.3 Packaging
7.1.3 Market Forecast
7.2 Upstream
7.2.1 Market Trends
7.2.2 Key Segments
7.2.2.1 Mammalian Expression Systems
7.2.2.2 Bacterial Expression Systems
7.2.2.3 Yeast Expression Systems
7.2.2.4 Baculovirus/Insect Expression Systems
7.2.2.5 Others
7.2.3 Market Forecast
8 Market Breakup by Application
8.1 Human Use
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Veterinary
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Ajinomoto Co. Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Albany Molecular Research Inc
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 SWOT Analysis
14.3.3 Catalent Inc
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Cobra Biologics Limited (Charles River Laboratories International Inc.)
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.5 Cytovance Biologics Inc. (Hepalink USA Inc.)
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.6 Fujifilm Holdings Corporation
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 ICON plc
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 IDT Biologika GmbH
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.9 Lonza Group AG
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Merck KGaA
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Pharmaceutical Product Development LLC
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis
14.3.12 PRA Health Sciences Inc.
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 Financials
Figure 2: Global: Vaccine Contract Manufacturing Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Vaccine Contract Manufacturing Market: Breakup by Vaccine Type (in %), 2021
Figure 5: Global: Vaccine Contract Manufacturing Market: Breakup by Workflow (in %), 2021
Figure 6: Global: Vaccine Contract Manufacturing Market: Breakup by Application (in %), 2021
Figure 7: Global: Vaccine Contract Manufacturing Market: Breakup by Region (in %), 2021
Figure 8: Global: Vaccine Contract Manufacturing (Attenuated) Market: Sales Value (in Million US$), 2016 & 2021
Figure 9: Global: Vaccine Contract Manufacturing (Attenuated) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 10: Global: Vaccine Contract Manufacturing (Inactivated) Market: Sales Value (in Million US$), 2016 & 2021
Figure 11: Global: Vaccine Contract Manufacturing (Inactivated) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 12: Global: Vaccine Contract Manufacturing (Subunit-based) Market: Sales Value (in Million US$), 2016 & 2021
Figure 13: Global: Vaccine Contract Manufacturing (Subunit-based) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 14: Global: Vaccine Contract Manufacturing (Toxoid-based) Market: Sales Value (in Million US$), 2016 & 2021
Figure 15: Global: Vaccine Contract Manufacturing (Toxoid-based) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 16: Global: Vaccine Contract Manufacturing (DNA-based) Market: Sales Value (in Million US$), 2016 & 2021
Figure 17: Global: Vaccine Contract Manufacturing (DNA-based) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 18: Global: Vaccine Contract Manufacturing (Downstream) Market: Sales Value (in Million US$), 2016 & 2021
Figure 19: Global: Vaccine Contract Manufacturing (Downstream) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 20: Global: Vaccine Contract Manufacturing (Upstream) Market: Sales Value (in Million US$), 2016 & 2021
Figure 21: Global: Vaccine Contract Manufacturing (Upstream) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 22: Global: Vaccine Contract Manufacturing (Human Use) Market: Sales Value (in Million US$), 2016 & 2021
Figure 23: Global: Vaccine Contract Manufacturing (Human Use) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 24: Global: Vaccine Contract Manufacturing (Veterinary) Market: Sales Value (in Million US$), 2016 & 2021
Figure 25: Global: Vaccine Contract Manufacturing (Veterinary) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 26: North America: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 27: North America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 28: United States: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 29: United States: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 30: Canada: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 31: Canada: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 32: Asia-Pacific: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 33: Asia-Pacific: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 34: China: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 35: China: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 36: Japan: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 37: Japan: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 38: India: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 39: India: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 40: South Korea: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 41: South Korea: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 42: Australia: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 43: Australia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 44: Indonesia: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 45: Indonesia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 46: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 47: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 48: Europe: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 49: Europe: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 50: Germany: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 51: Germany: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 52: France: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 53: France: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 54: United Kingdom: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 55: United Kingdom: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 56: Italy: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 57: Italy: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 58: Spain: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 59: Spain: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 60: Russia: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 61: Russia: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 62: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 63: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 64: Latin America: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 65: Latin America: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 66: Brazil: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 67: Brazil: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 68: Mexico: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 69: Mexico: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 70: Others: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 71: Others: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 72: Middle East and Africa: Vaccine Contract Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 73: Middle East and Africa: Vaccine Contract Manufacturing Market: Breakup by Country (in %), 2021
Figure 74: Middle East and Africa: Vaccine Contract Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: Global: Vaccine Contract Manufacturing Industry: SWOT Analysis
Figure 76: Global: Vaccine Contract Manufacturing Industry: Value Chain Analysis
Figure 77: Global: Vaccine Contract Manufacturing Industry: Porter's Five Forces Analysis